Acute promyelocytic leukemia medical therapy: Difference between revisions
(Category) |
Shyam Patel (talk | contribs) |
||
| Line 8: | Line 8: | ||
Treatment options for patients with relapsed disease include [[arsenic trioxide]] and [[bone marrow transplant|allogeneic stem cell transplant]]. Monitoring for relapse using PCR tests for ''RARα'' allows early re-treatment which is successful in many instances. | Treatment options for patients with relapsed disease include [[arsenic trioxide]] and [[bone marrow transplant|allogeneic stem cell transplant]]. Monitoring for relapse using PCR tests for ''RARα'' allows early re-treatment which is successful in many instances. | ||
===Anti-leukemic Therapies=== | |||
*'''All-''trans'' retinoic acid''': | |||
*'''Arsenic trioxide''': | |||
**''Adverse effects: The adverse effects of arsenic trioxide include myelosuppression, liver dysfunction, QT interval prolongation, liver dysfunction.<ref name="pmid28352191">{{cite journal| author=McCulloch D, Brown C, Iland H| title=Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. | journal=Onco Targets Ther | year= 2017 | volume= 10 | issue= | pages= 1585-1601 | pmid=28352191 | doi=10.2147/OTT.S100513 | pmc=5359123 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28352191 }} </ref> | |||
===Supportive Therapies=== | |||
==References== | ==References== | ||
Revision as of 00:25, 30 April 2018
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia medical therapy |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
APL is unique among the leukemias distinguished by its sensitivity to all-trans retinoic acid (ATRA), a derivative of vitamin A. Treatment with ATRA causes differentiation of the immature leukemic promyelocytes into mature granulocytes. ATRA is typically combined with anthracycline based chemotherapy resulting in a clinical remission in approximately 90% of patients.
ATRA therapy is associated with the unique side effect of retinoic acid syndrome. This is associated with the development of dyspnea, fever, weight gain, peripheral edema and is treated with dexamethasone. The etiology of retinoic acid syndrome has been attributed to capillary leak syndrome from cytokine release from the differentiating promyelocytes.
Treatment options for patients with relapsed disease include arsenic trioxide and allogeneic stem cell transplant. Monitoring for relapse using PCR tests for RARα allows early re-treatment which is successful in many instances.
Anti-leukemic Therapies
- All-trans retinoic acid:
- Arsenic trioxide:
- Adverse effects: The adverse effects of arsenic trioxide include myelosuppression, liver dysfunction, QT interval prolongation, liver dysfunction.[1]
Supportive Therapies
References
- ↑ McCulloch D, Brown C, Iland H (2017). "Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives". Onco Targets Ther. 10: 1585–1601. doi:10.2147/OTT.S100513. PMC 5359123. PMID 28352191.